<SEC-DOCUMENT>0001683168-19-002931.txt : 20190916
<SEC-HEADER>0001683168-19-002931.hdr.sgml : 20190916
<ACCEPTANCE-DATETIME>20190916093010
ACCESSION NUMBER:		0001683168-19-002931
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190912
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190916
DATE AS OF CHANGE:		20190916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		191093907

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>September 12, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-37487</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13-3632859</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9635 Granite Ridge Drive, Suite 100</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92123</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: 858-459-7800 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AEMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 1.01</B></TD><TD><B>Entry Into A Material Definitive Agreement.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 12, 2019, Aethlon Medical, Inc. (the &ldquo;Company&rdquo;) entered into an SBIR Phase II Award Contract with the National
Institutes of Health (&ldquo;NIH&rdquo;) and the National Cancer Institute (&ldquo;NCI&rdquo;), for NIH/NCI Topic 359, entitled
&ldquo;<I>A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring</I>&rdquo; (the &ldquo;Award
Contract&rdquo;). The Award Contract amount is $1,860,561 and runs for the period from September 16, 2019 through September 15,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The work to be performed
pursuant to this Award Contract will focus on melanoma exosomes. This work follows from the Company&rsquo;s completion of a Phase
I contract for the Topic 359 solicitation that ran from September 2017 through June 2018. Following on the Phase I work, the deliverables
in the Company&rsquo;s Phase II program will involve the design and testing of a pre-commercial prototype of a more advanced version
of the exosome isolation platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 81%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="aethlon_8k-ex9901.htm">Press Release dated September 16, 2019.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aethlon Medical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: September 16, 2019</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 51%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James B. Frakes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James B. Frakes</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 93px; width: 225px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical Receives National Cancer
Institute Contract Award</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>$1.86 Million Over Two Years to Develop
Device for Isolating Exosomes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO (September 16, 2019) &ndash;
Aethlon Medical, Inc. (<B>Nasdaq: AEMD</B>), a therapeutic technology company focused on unmet needs in global health, announced
today that the National Cancer Institute (NCI) has awarded the Company an SBIR Phase 2 contract for Topic 359, a solicitation entitled
&ldquo;Technologies for Differential Isolation of Exosomes and Oncosomes.&rdquo; This solicitation prioritized the advancement
of technologies for isolating exosomes from biofluids for applications in oncology research and clinical care. This contract will
be funded with Federal funds from the NCI, National Institutes of Health, Department of Health and Human Services, under Contract
No. 75N91019C00042.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exosomes are nanoparticles that are abundantly
released from cancer cells and carry the complement of a tumor&rsquo;s genetic and protein cargo, making them important targets
for non-invasive liquid biopsies in cancer. Aethlon is actively developing assays in this area through its majority-owned subsidiary,
Exosome Sciences, Inc. However, there remains a need for high-throughput and selective technologies which isolate exosomes from
various bodily fluids that could be adopted in clinical workflows. A technology that resolves the bottleneck in methods for obtaining
pure populations of exosomes is anticipated to have wide applicability to be paired with downstream genomic sequencing, proteomic
profiling tests and, potentially, for the development of therapeutic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon&rsquo;s contract, entitled &ldquo;<I>A
Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring</I>&rdquo;, will potentially advance
a device having the capabilities of isolating exosomes derived from cancer cells and from the bulk of other vesicles and complex
proteins present in fresh and archived biofluids. The work to be performed will focus on melanoma exosomes, with anticipated wider
applicability to other cancer types. This work follows from Aethlon&rsquo;s successful completion of a Phase I contract for the
Topic 359 solicitation that ran from September 2017 through June 2018. The Phase I work demonstrated the capabilities of a laboratory
version of Aethlon&rsquo;s proprietary technology, the Hemopurifier, as an exosome-isolation device by processing biofluid samples
to obtain intact preparations of melanoma exosomes. Following on the Phase I work, the deliverables in the Phase II program will
involve the design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform. The
goal is for the device platform to be optimized for applicability in workflows to leverage the untapped potential of exosomes for
diagnostic and therapeutic monitoring in melanoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NCI Phase II contract period runs from
September 16, 2019 through September 15, 2021. The total amount of the firm fixed price contract is $1,860,561. Under this contract,
Aethlon plans to collaborate with researchers at the University of Pittsburgh Medical Center in Pittsburgh, PA and Massachusetts
General Hospital in Boston, MA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc. also is continuing the development of
its proprietary Hemopurifier, which is a first in class therapeutic device designed for the single use depletion of circulating
viruses and cancer-promoting exosomes. The Hemopurifier has previously been designated a Breakthrough Device by the FDA for the
treatment of glycosylated viruses, including Ebola and other hemorrhagic fever viruses, and in late 2018 was additionally designated
as a Breakthrough Device &ldquo;&hellip;for the treatment of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development
or severity of the disease&hellip;.&rdquo;. Following discussions and a meeting with FDA, the Company is now preparing for the
initiation of clinical trials in cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc. is focused on addressing unmet needs in
global health. The Aethlon Hemopurifier&reg; is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening
viral infections. In cancer, the Hemopurifier&reg; depletes the presence of circulating tumor-derived exosomes that promote immune
suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier&reg; is an FDA
designated &quot;Breakthrough Device&quot; related to the treatment of individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate
in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to
life-threatening viruses that are not addressed with approved therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which
is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks
and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot; &quot;expect,&quot;
&quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot; &ldquo;potentially&rdquo;
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks
and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors
that may contribute to such differences include, without limitation, the Company's ability to successfully complete the contract
with the NIH, or raise additional funds and maintain its listing on the Nasdaq Capital Market, or any other national securities
exchange, the risk that the Company&rsquo;s subsidiary will not be able to commercialize its products, that the FDA will not approve
the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's
ability to complete the development of the Hemopurifier and other planned products, the Company's ability to manufacture its products
either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary
technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors.
The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results
to differ materially from those anticipated in forward-looking statements can be found under the caption &quot;Risk Factors&quot;
in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities
and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend,
nor does it undertake any duty, to update this information to reflect future events or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 x3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Schull or Maggie Beller</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Russo Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David.Schull@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maggie.Beller@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212-845-4271</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !T 1D# 2(  A$! Q$!_\0
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M@J>TL;B^F$-K TLAZ!17(\*M[G6L2^QR7A"_NM$UV*1K>5H)_P!U.@4\J?\
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M2<MV7&G&.R$I:**@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
